Should I buy or sell Longboard Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LBPH shares. View LBPH analyst ratings or view top-rated stocks .

What is Longboard Pharmaceuticals' stock price target for 2024?

6 Wall Street analysts have issued 12-month target prices for Longboard Pharmaceuticals' stock. Their LBPH share price targets range from $13.00 to $60.00. On average, they predict the company's share price to reach $39.50 in the next year. This suggests a possible upside of 126.5% from the stock's current price. View analysts price targets for LBPH or view top-rated stocks among Wall Street analysts .

How have LBPH shares performed in 2024?

Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of the year. Since then, LBPH shares have increased by 189.2% and is now trading at $17.44. View the best growth stocks for 2024 here .

Are investors shorting Longboard Pharmaceuticals?

Longboard Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 32.4% from the March 15th total of 3,740,000 shares. Based on an average daily trading volume, of 644,800 shares, the short-interest ratio is currently 7.7 days. Currently, 14.9% of the shares of the stock are sold short. View Longboard Pharmaceuticals' Short Interest .

When is Longboard Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LBPH earnings forecast .

How were Longboard Pharmaceuticals' earnings last quarter?

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02.

What ETFs hold Longboard Pharmaceuticals' stock?

ETFs with the largest weight of Longboard Pharmaceuticals (NASDAQ:LBPH) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

When did Longboard Pharmaceuticals IPO?

Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

Who are Longboard Pharmaceuticals' major shareholders?

Longboard Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.03%). View institutional ownership trends .

How do I buy shares of Longboard Pharmaceuticals?

Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free LBPH Stock Alerts

$17.44

-0.57 (-3.16%)

(As of 04/19/2024 ET)

Compare

Today's Range: $17.32
▼
$18.39
50-Day Range: $17.00
▼
$23.94
52-Week Range: $3.60
▼
$28.15

Volume: 521,796 shs
Average Volume: 1.32 million shs
Market Capitalization: $628.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.50

Get Longboard Pharmaceuticals alerts:

Longboard Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 126.5% Upside
$39.50 Price Target
Short Interest: Bearish
14.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.75
Based on 8 Articles This Week
Insider Trading: Selling Shares
$96.48 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.01) to ($2.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

697th out of 911 stocks

Pharmaceutical Preparations Industry

307th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Longboard Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Longboard Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.91% of the float of Longboard Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Longboard Pharmaceuticals has recently increased by 32.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Longboard Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Longboard Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LBPH.

2.6

News and Social Media Coverage

News Sentiment
Longboard Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Longboard Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Longboard Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,479,595.00 in company stock.
Percentage Held by Insiders
Only 5.57% of the stock of Longboard Pharmaceuticals is held by insiders.
Percentage Held by Institutions
63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($2.01) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Longboard Pharmaceuticals is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Longboard Pharmaceuticals is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Longboard Pharmaceuticals has a P/B Ratio of 10.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

LBPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LBPH Stock News Headlines

April 17, 2024 | markets.businessinsider.com

Bexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster Status

April 17, 2024 | americanbankingnews.com

Longboard Pharmaceuticals' (LBPH) "Buy" Rating Reaffirmed at HC Wainwright

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 15, 2024 | americanbankingnews.com

Short Interest in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Increases By 32.4%

April 14, 2024 | americanbankingnews.com

Longboard Pharmaceuticals (NASDAQ:LBPH) Stock Price Down 5.6%

April 11, 2024 | americanbankingnews.com

Longboard Pharmaceuticals' (LBPH) "Overweight" Rating Reiterated at Cantor Fitzgerald

April 11, 2024 | americanbankingnews.com

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Average Recommendation of "Buy" by Analysts

April 3, 2024 | businesswire.com

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | businesswire.com

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 27, 2024 | finance.yahoo.com

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%

March 16, 2024 | finance.yahoo.com

LBPH Apr 2024 17.500 put

March 14, 2024 | finance.yahoo.com

Longboard Pharmaceuticals Inc Reports Full Year 2023 Financial Results

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Longboard Pharmaceuticals’ Bexicaserin Shows Promising Efficacy and Strategic Milestones

March 12, 2024 | benzinga.com

Recap: Longboard Pharmaceuticals Q4 Earnings

March 12, 2024 | businesswire.com

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

March 3, 2024 | finance.yahoo.com

LBPH May 2024 30.000 call

March 1, 2024 | businesswire.com

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 24, 2024 | finance.yahoo.com

LBPH Mar 2024 22.500 call

February 24, 2024 | finance.yahoo.com

LBPH Aug 2024 15.000 put

February 22, 2024 | benzinga.com

Longboard Pharmaceuticals Stock (NASDAQ:LBPH), Short Interest Report

February 21, 2024 | finance.yahoo.com

Longboard Pharmaceuticals, Inc. (LBPH)

February 16, 2024 | msn.com

Longboard stock up 8% as Citi initiates at buy, citing takeover potential

February 5, 2024 | ca.finance.yahoo.com

LBPH Feb 2024 30.000 call

February 2, 2024 | finance.yahoo.com

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 1, 2024 | finance.yahoo.com

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

January 26, 2024 | msn.com

TCBP and PCSA among pre-market losers

See More Headlines

Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LBPH
CUSIP: N/A
CIK: 1832168
Web: www.longboardpharma.com
Phone: 619-592-9775
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.50
High Stock Price Target: $60.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +120.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.53%
Return on Assets: -85.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.14
Quick Ratio: 5.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 10.71

Miscellaneous

Outstanding Shares: 36,020,000
Free Float: 34,011,000
Market Cap: $644.40 million
Optionable: Optionable
Beta: 1.24

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Kevin R. Lind (Age 48)
President, CEO, Secretary & Director
Comp: $961.85k
Ms. Brandi L. Roberts CPA (Age 50)
M.B.A., Executive VP & CFO
Comp: $610.07k
Dr. Randall E. Kaye M.D. (Age 62)
Executive VP & Chief Medical Officer
Comp: $629.03k
Mr. Chadwick J. Orevillo MPH
Executive VP & Head of Operations
Megan E. Knight
VP & Head of Investor Relations
Mr. Steven W. Spector J.D. (Age 59)
Executive VP, Head of Business Development & General Counsel
Dr. Anne M. Danks Ph.D.
VP & Head of Nonclinical Research & Development
Mr. Gus Cardenas
VP & Head of Quality Assurance
Dr. Marco Peters Ph.D.
VP & Head of Translational Science
Dr. Dewey McLin Ph.D.
VP & Head of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LBPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Longboard Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LBPH shares.
View LBPH analyst ratings or view top-rated stocks.
What is Longboard Pharmaceuticals' stock price target for 2024?: 6 Wall Street analysts have issued 12-month target prices for Longboard Pharmaceuticals' stock. Their LBPH share price targets range from $13.00 to $60.00. On average, they predict the company's share price to reach $39.50 in the next year. This suggests a possible upside of 126.5% from the stock's current price.
View analysts price targets for LBPH or view top-rated stocks among Wall Street analysts.
How have LBPH shares performed in 2024?: Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of the year. Since then, LBPH shares have increased by 189.2% and is now trading at $17.44.
View the best growth stocks for 2024 here.
Are investors shorting Longboard Pharmaceuticals?: Longboard Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 32.4% from the March 15th total of 3,740,000 shares. Based on an average daily trading volume, of 644,800 shares, the short-interest ratio is currently 7.7 days. Currently, 14.9% of the shares of the stock are sold short.
View Longboard Pharmaceuticals' Short Interest.
When is Longboard Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LBPH earnings forecast.
How were Longboard Pharmaceuticals' earnings last quarter?: Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02.

What ETFs hold Longboard Pharmaceuticals' stock?: ETFs with the largest weight of Longboard Pharmaceuticals (NASDAQ:LBPH) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
When did Longboard Pharmaceuticals IPO?: Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.
Who are Longboard Pharmaceuticals' major shareholders?: Longboard Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.03%).
View institutional ownership trends.
How do I buy shares of Longboard Pharmaceuticals?: Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LBPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

Longboard Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

LBPH Stock Price History

LBPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LBPH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™